Lv11
35 积分 2021-10-18 加入
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
1小时前
已完结
Can we learn from failures? A systematic review of phase III trials in platinum-resistant ovarian cancer
1小时前
求助中
The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
4天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
8天前
已完结
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
21天前
已关闭
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
23天前
已完结
Maximizing therapeutic potential and safety: Exploring multi/dual-payload antibody conjugates as cancer theranostics
1个月前
已完结
Dual-payload ADCs move into first oncology clinical trials
1个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
1个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
1个月前
已完结
皖公网安备34019202002308
